
LucentAD® p-Tau 217
Special Instructions
This assay currently is not available in New York State
Expected Turnaround Time
10 business days

Using and Interpreting the Results
| Likelihood of Amyloid Pathology | Interpretation |
|
<0.040 |
Low likelihood of amyloid pathology. Other causes should be considered |
|
0.041 – 0.089 |
Intermediate likelihood. Further testing (CSF/PET) may be required |
|
>0.090 |
High likelihood of amyloid pathology. Consistent with Alzheimer’s disease |
LucentAD® p-Tau 217 is not a standalone diagnostic test. It is meant to be used alongside clinical assessments for a comprehensive diagnostic evaluation.
